Novartis and MorphoSys Achieve Breakthrough in Sjögren’s Disease Treatment with Successful Phase III Trials
Novartis and MorphoSys AG have achieved a breakthrough in treating Sjögren’s disease with the successful completion of two Phase III clinical trials for the drug candidate ianalumab.
2 minutes to read